Australia Stock Exchange release from NEUREN PHARMACEU : S&P DJI Announces March 2022 Quarterly Rebalance
04/03/2022 06:03
Australia Stock Exchange release from NEUREN PHARMACEU NEU.AX : S&P DJI Announces March 2022 Quarterly Rebalance
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union